This is especially the case for many hematologic malignancies (HM) [5], as demonstrated by a promising target of immune-mediated antitumour responses: PR1, a nine-amino acid-long HLA-A2-restricted peptide, which derives from proteinase 3 (PR3). This evidence concerns the gene PRTN3 and hematologic disorder.